DMPK Services – Supporting Drug Discovery with 40-years of Expertise

Focused on fast optimization of lead structures toward a viable clinical candidate. All studies are supported by our experienced bioanalysis.

NUVISAN is a leading provider of drug metabolism and pharmacokinetics (DMPK) solutions for the pharmaceutical industry. Our services cover the entire DMPK spectrum, from in vitro PK and DDI to in vivo DMPK, biotransformation and metabolite identification (MetID), consultancy services, isotope chemistry, and bioanalysis. With our vast scientific experience and our well-strategized study designs we provide you quickly and flexibly with reliable data to support you in the development of safe and effective drugs. Committed to quality and efficiency, we work closely with you to design solutions that meet your goals.

Get in Touch

In Vitro PK & DDI

In Vivo DMPK

Consultancy Services

Discovery Bioanalysis

To deliver high-quality solutions to our clients, we adhere to high standards for the development and manufacturing of your medicines:

Innovative research environment

Our facilities are among the top 5% of life science chemistry laboratories with state-of-the-art equipment.

Reliable project implementation

Over 95% of our projects are delivered on time and on budget, which is highly valued by our customers.

Team of experts

Our specialists have an average of 10+ years' experience in life science chemistry projects.

Drug Discovery DMPK

At NUVISAN, we are dedicated to provide exceptional DMPK services that support you in making informed decisions throughout the drug discovery and development process. DMPK discovery studies are specifically focusing on the identification and optimization of lead structures to establish a viable clinical candidate.

The initial step comprises the use of in vitro-techniques to identify lead molecules with “drug-like” ADME properties and favorable physicochemistry. Some of our assays can be performed with a high-throughput design for fast screening of compound libraries. The initial in vitro investigations facilitate and complement the identification of suitable lead compounds for in vivo pharmacokinetic studies.

Depending on your compound profile and needs, customized in vivo study designs are conducted by our DMPK experts to provide an early PK profile analysis for further lead optimization in view of the selection of a promising candidate. High animal welfare standards that align with the 3R-concept and AAALAC accreditation are the basis of our work. Furthermore, the test of different formulations to identify the best one for other in vivo studies is our expertise.

In Vitro PK & DDI

Our in vitro compound profiling services includes in vitro metabolic stability (liver microsomes and hepatocytes), permeability and transporters, in vitro protein binding and blood partitioning, CYP inhibition (reversible and irreversible), and CYP induction. We offer data rapidly, reliably, and of the highest quality and provide scientific support by explanation of the results and the suggestion of appropriate screening strategies to overcome ADME liabilities.

Discover More

In Vivo DMPK

Creating compounds with a profound pharmacokinetic profile can be challenging. With more than 20 years of drug metabolism and pharmacokinetics (DMPK) expertise, our scientists can identify relevant drug metabolism and pharmacokinetic liabilities for you. Multiple assay types and in vivo models deliver all of the data needed for your compound optimization and clinical candidate selection.

Discover More

Consultancy Services

Based on long-term pharmaceutical research experience, DMPK scientists offer consultancy on drug metabolism and pharmacokinetics (PK) for all stages of your drug discovery project, from hit identification to preclinical candidate profiling. We have strong expertise in interpreting in vitro and in vivo DMPK data in the specific project context and in how to identify and overcome DMPK-related development risks early.

Discover More

Discovery Bioanalysis

Discovery bioanalysis focuses on the identification and quantification of drugs, metabolites, and proteins in biological systems. It plays a crucial role in drug development and biomarker discovery. The insights gained from our scientists in discovery bioanalysis can support you with solutions specifically tailored to your project needs—from target identification and validation all the way to lead optimization and in-depth characterizations of clinical candidates.

Discover More

From Discovery further Down the Road Towards Development and IND

NUVISAN´s discovery experience guides you towards your candidate drug and paves the way to further developmental DMPK studies in view of IND submission for Phase I studies.

With this regard, we support you with thorough in vitro biotransformation studies on the selection of appropriate tox species by doing an interspecies comparison in e.g. hepatocyte suspensions. Accompanied by our experience in developmental toxicology studies, we can pinpoint the starting dose for first-in-human/first-in-patient clinical trials.

Our radiochemists are additionally able to provide your asset in a radiolabeled form, which greatly enhances metabolite identification, and moreover, helps you to do an early quantitative estimation of known human metabolites in plasma samples from non-radioactive Phae I trials.

Getting from early discovery to Phase I as safely and efficiently as possible poses a high competitive advantage for drug creators. NUVISAN´s experts navigate you through the discovery and development landscape with best-in-class solutions, which address the specific challenges of your individual project.

DMPK Services – Supporting Drug Discovery with 40-years of Expertise

Focused on fast optimization of lead structures toward a viable clinical candidate. All studies are supported by our experienced bioanalysis.

In Vitro PK & DDI

In Vivo DMPK

Consultancy Services

Discovery Bioanalysis

Get in Touch!

Stephanie Urschel

VP of Business Development, Europe

Innovative research environment

Reliable project implementation

Team of experts

Drug Discovery DMPK

In Vitro PK & DDI

In Vivo DMPK

Consultancy Services

Discovery Bioanalysis

From Discovery further Down the Road Towards Development and IND

Get in Touch!

Stephanie Urschel
VP of Business Development, Europe

stephanie.urschel@nuvisan.com